The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Hemophilia B Gene Therapy Market During The Forecast Period 2026–2030?
The hemophilia b gene therapy market has experienced rapid expansion in recent years. Projections indicate it will grow from $0.55 billion in 2025 to $0.71 billion in 2026, maintaining a compound annual growth rate (CAGR) of 29.6%. Historically, this growth can be attributed to enhancements in gene delivery technologies, a deeper understanding of hemophilia b genetics, the expansion of clinical research programs, the increasing challenge posed by lifelong replacement therapy, and the availability of specialized treatment centers.
The hemophilia b gene therapy market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $2.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.8%. This projected expansion during the forecast period is driven by factors such as increasing approvals for gene therapies, growing investments in treatments for rare diseases, a rising demand for enduring therapeutic outcomes, the expansion of advanced manufacturing capabilities, and an increase in patient access programs. Significant trends expected in this period include ongoing progress in one-time curative therapies, a heightened focus on long-term factor IX expression, continuous optimization of AAV vector design, the expansion of personalized gene therapy strategies, and enhanced regulatory alignment for advanced therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp
What Key Drivers Are Influencing The Growth Of The Hemophilia B Gene Therapy Market?
The increasing number of gene therapy clinical trials is anticipated to boost the growth of the hemophilia B gene therapy market in the future. These trials are research studies designed to evaluate the safety, effectiveness, and long-term therapeutic potential of gene-based treatments in human subjects. The increase in gene therapy clinical trials is propelled by greater investment from biopharmaceutical companies, advancements in viral vector technology, supportive regulatory frameworks, and the necessity to address rare genetic disorders with high unmet medical needs, including hemophilia B. Hemophilia B gene therapy benefits from this expanding clinical trial landscape by utilizing established clinical development pathways, regulatory expertise, and manufacturing capabilities associated with in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA), a UK-based national trade association, reported that the UK had 193 ongoing advanced therapy clinical trials, similar to 2024, with more than half in early stages, approximately 80% commercially sponsored, and over 80% focused on gene therapies, equally divided between ex vivo and in vivo approaches. Consequently, the growing number of cell and gene therapy clinical trials is propelling the hemophilia B gene therapy market’s expansion.
What Market Segments Are Evaluated Within The Hemophilia B Gene Therapy Market?
The hemophilia b gene therapy market covered in this report is segmented –
1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors
2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
3) By Treatment Type: On-Demand; Cure; Prophylaxis
4) By Patient Age Group: Geriatric; Adults; Pediatric
5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
Subsegments:
1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors
2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors
3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors
What Industry Trends Are Redefining The Hemophilia B Gene Therapy Market?
Leading companies within the hemophilia B gene therapy market are increasingly prioritizing innovations in advanced gene delivery platforms, notably optimized adeno-associated virus (AAV)–based vector systems, to enhance both therapeutic efficacy and patient safety. These optimized AAV-based vector systems serve as sophisticated viral delivery mechanisms that facilitate the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, thereby supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, the first gene therapy sanctioned for the treatment of hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who do not have a history of factor IX inhibitors and aims to reduce or eliminate the necessity for routine factor IX prophylaxis. Based on results from the pivotal HOPE-B clinical study, a considerable number of treated patients no longer required regular factor IX infusions, showcasing sustained therapeutic benefit and emphasizing the potential of next-generation AAV-based gene therapies in managing the disease long-term.
Which Companies Hold Significant Positions In The Hemophilia B Gene Therapy Market?
Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.
Read the full hemophilia b gene therapy market report here:
https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report
Which Global Regions Are Shaping The Competitive Landscape Of The Hemophilia B Gene Therapy Market?
North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Hemophilia B Gene Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33162&type=smp
Browse Through More Reports Similar to the Global Hemophilia B Gene Therapy Market 2026, By The Business Research Company
Hepatitis Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Acquired Hemophilia Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report
Hemophilia Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model